Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.
A promising approach to improving outcomes in patients with cryptococcal meningitis is to use adjunctive passive immunotherapy with a monoclonal antibody (MAb) directed against the capsular polysaccharide of Cryptococcus neoformans. This is the first application of MAb therapy for the treatment of a fungal disease in humans. We determined the safety and maximum tolerated dose of the murine anticryptococcal MAb 18B7 in a phase I dose-escalation study. The subjects were human immunodeficiency virus-infected patients who had been successfully treated for cryptococcal meningitis. Six dosing cohorts received MAb 18B7 at 0.01 to 2 mg/kg of body weight as a single infusion. Three patients each received 0.01, 0.05, 0.2, and 0.5 mg of MAb 18B7 per kg without significant adverse events. Four of the subjects who received the 1-mg/kg dose had mild study drug-associated toxicity, including transient nausea, vomiting, back pain, and urticarial rash. Two of the subjects who received 2 mg/kg developed drug-associated mild to moderate nausea, vomiting, chills, and myalgias. One of the subjects who received 2 mg/kg developed intracranial hypertension 10 weeks after MAb 18B7 administration. Serum cryptococcal antigen titers in the cohorts receiving doses of 1 and 2 mg/kg declined by a median of twofold at 1 week and a median of threefold at 2 weeks postinfusion, but the titers subsequently returned toward the baseline values by week 12. The half-life of MAb 18B7 in serum was approximately 53 h, while the MAb was undetectable in the cerebrospinal fluid of all patients. These data support the continued investigation of MAb 18B7 at a maximum single dose of 1.0 mg/kg.
Larsen
Robert A
RA
Department of Medicine (Infectious Diseases), 2020 Zonal Ave., IRD Room 632, MC 9520, University of Southern California, Los Angeles, CA 90033, USA. rlarsen@usc.edu
Pappas
Peter G
PG
Perfect
John
J
Aberg
Judith A
JA
Casadevall
Arturo
A
Cloud
Gretchen A
GA
James
Robert
R
Filler
Scott
S
Dismukes
William E
WE
D000818:Animals; D000908:Antibodies, Fungal / Q000009:adverse effects* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000493:pharmacokinetics; D000946:Antigens, Fungal / Q000097:blood; D019540:Area Under Curve; D003455:Cryptococcus neoformans / Q000276:immunology*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007116:Immunization, Passive; D016919:Meningitis, Cryptococcal / Q000628:therapy*; D051379:Mice
D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D000946:Antigens, Fungal
J Infect Dis. 1991 May;163(5):1114-20
2019759
AIDS Res Hum Retroviruses. 1994 Sep;10(9):1079-87
7826695
Lancet. 1992 Jan 4;339(8784):21-3
1370335
Antimicrob Agents Chemother. 1992 Mar;36(3):690-2
1622188
Infect Immun. 1992 Nov;60(11):4534-41
1398966
J Immunol. 2000 Apr 15;164(8):4367-74
10754337
Infect Immun. 1995 Jul;63(7):2632-44
7790079
Infect Immun. 1995 Aug;63(8):2919-23
7622213
Infect Immun. 1995 Sep;63(9):3448-53
7642276
J Neuroimmunol. 1995 Oct;62(1):43-52
7499491
Antimicrob Agents Chemother. 1995 Jul;39(7):1398-405
7492075
J Clin Invest. 1996 Feb 1;97(3):689-98
8609224
J Infect Dis. 1996 May;173(5):1222-31
8627076
J Med Vet Mycol. 1996 Jan-Feb;34(1):19-30
8786467
Infect Immun. 1996 Jul;64(7):2846-9
8698522
Infect Immun. 1996 Aug;64(8):2897-903
8757810
Clin Infect Dis. 1995 Dec;21(6):1477-9
8749638
J Antimicrob Chemother. 1996 Mar;37(3):617-22
9182119
J Immunol. 1997 Jan 15;158(2):790-9
8992996
Infect Immun. 1997 May;65(5):1800-7
9125564
N Engl J Med. 1997 Jul 3;337(1):15-21
9203426
J Infect Dis. 1997 Aug;176(2):485-91
9237716
Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46
9624491
Clin Infect Dis. 1999 Jan;28(1):82-92
10028076
AIDS. 1999 Apr 16;13(6):653-60
10397559
J Infect Dis. 1999 Sep;180(3):791-801
10438368
Am J Pathol. 1964 Jul;45:1-19
14172716
Arch Neurol. 1964 Dec;11:632-41
14202180
J Infect Dis. 1964 Oct;114:373-7
14217937
Arch Neurol. 1965 Feb;12:189-96
14237776
Med Mycol. 2000 Dec;38(6):407-17
11204878
J Immunol. 2002 Aug 1;169(3):1379-86
12133962
J Clin Microbiol. 2004 Jun;42(6):2786-8
15184471
Infect Immun. 1972 Jun;5(6):896-901
4564405
J Immunol. 1978 May;120(5):1686-90
351055
N Engl J Med. 1979 Jul 19;301(3):126-31
449951
Sabouraudia. 1981 Dec;19(4):237-44
7034236
J Immunol. 1982 Oct;129(4):1675-80
7050244
Infect Immun. 1987 Mar;55(3):749-52
3546140
Hybridoma. 1989 Apr;8(2):231-9
2785482
Ann Intern Med. 1990 Aug 1;113(3):183-7
2197908
J Exp Med. 1993 Apr 1;177(4):1105-16
8459205
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3636-40
8475112
J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):42-52
8110730
Infect Immun. 1994 Mar;62(3):1079-88
8112842
Antimicrob Agents Chemother. 1994 Mar;38(3):580-7
8203858
Clin Infect Dis. 1994 Oct;19(4):741-5
7803641
Infect Immun. 1995 Feb;63(2):573-9
7822024
N Engl J Med. 1992 Jan 9;326(2):83-9
1727236